US EditionPublished • loading... • Updated
AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B
Summary by The Billings Gazette
31 Articles
31 Articles
Helena Independent Record+30 Reposted by 30 other sources
AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B
SAN FRANCISCO, Sept. 21, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), today…
·Helena, United States
Read Full ArticleCoverage Details
Total News Sources31
Leaning Left2Leaning Right0Center15Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
12%
C 88%
Factuality
To view factuality data please Upgrade to Premium
